EpiVario Inc. — SEC Form D Filing

EpiVario Inc. filed an SEC Form D on October 13, 2026, reporting $185K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
October 13, 2026
Amount reported
$185K
Round stage
Pre-seed stage based on the small $185,000 debt raise intended for early research and operational runway.
Industry
Pharmaceuticals
Website
https://www.epivario.com

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Neuropsychiatric and addiction disorders often resist conventional treatments because existing therapies fail to target underlying epigenetic dysregulation.

Solution

EpiVario develops targeted pharmaceutical drug candidates designed to modify disease-related epigenetic processes to treat trauma, stress, and substance-use disorders.

Why now

Recent advances in understanding chromatin biology and epigenetic gene regulation enable precise pharmacological control over psychiatric gene expression and memory consolidation.

Source: SEC EDGAR Form D filing